
US pharmaceutical company Pfizer is hoping to push its way into the obesity drug market by acquiring biopharmaceutical firm Metsera for $4.9 billion (€4.16bn).
The deal brings Metsera's pipeline of therapies for obesity and cardiometabolic diseases, along with its expertise and infrastructure, into Pfizer's portfolio.